Inhibitors for BRD3/4 and MLL/WDR5 reverted the PLS gene expression, and inhibitors for HAT and BRD3/4 reverted the HCV-induced EGF and NFkB2 overexpression, which are risk factors for HCC development. Here, BRD3 is linked to hepatocellular carcinoma.